65 reports

  • JAPAN - CYSTIC FIBROSIS THERAPEUTICS MARKET (MILLION US$), 2014 - 2016
  • 6.2 CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET & FORECAST
  • Genetic Disorder
  • World
  • Market Size
  • AbbVie Inc.
  • Editas Medicine, Inc.

Genetic Disorders royalty rates Chapter ## – Leading Genetic Disorders deals and dealmakers ##. ##.

  • Genetic Disorder
  • Pathology
  • World
  • Key Trends
  • 5.2.2.4.4.4 REST OF MENA
  • Genetic Disorder
  • World
  • Forecast
  • Biocartis S.A.
  • Transgenomic, Inc.
  • DIAGNOSIS
  • KEY BUYING CRITERIA FOR GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET 2015

Dutch biotechnology company developing RNA therapeutics for genetic diseases.

  • Genetic Disorder
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Novartis AG
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders
  • Genetic Disorder
  • World
  • Aldagen, Inc.
  • Asklepion Pharmaceuticals, LLC
  • Nutra Pharma Corporation

Genetic Influences on Cystic Fibrosis Lung Disease Severity.

  • Genetic Disorder
  • World
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • PULMONARY HYPERTENSION

Engages in the development of drugs in areas such as immuno-oncology, oncology, immunoscience, virology, cardiovascular, fibrotic diseases, and metabolic and genetically defined diseases.

  • Genetic Disorder
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG

Genetic Influences on Cystic Fibrosis Lung Disease Severity.

  • Genetic Disorder
  • World
  • Market Size
  • AstraZeneca PLC
  • GlaxoSmithKline plc

Cystic fibrosis and bone disease: are we missing a genetic link?

  • Genetic Disorder
  • Mortality
  • Canada
  • Italy
  • Forecast
  • Snapshot of Cystic Fibrosis
  • 06. Introduction
  • Genetic Disorder
  • Europe
  • Actavis plc
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Clinical Trials by G7 Countries: Proportion of Primary Immune Deficiency (PID) to Genetic Disorders Clinical Trials
  • Clinical Trials by E7 Countries: Proportion of Primary Immune Deficiency (PID) to Genetic Disorders Clinical Trials
  • Genetic Disorder
  • World
  • Baxter International Inc.
  • Biotest AG
  • CSL Limited

Genetic Disorders, Infectious Diseases, Musculoskeletal Disorders, Neurologic Disorders, Respiratory Disorders, Skin Diseases, Transplantation, and Others.............. ## Table ##: Injectables Market by Segment Worldwide (2015) - Percentage Share Breakdow

  • Genetic Disorder
  • Pharmaceutical
  • China
  • World
  • Demand

Cystic fibrosis and bone disease: are we missing a genetic link?

  • Genetic Disorder
  • Forest Laboratories, Inc.
  • Novartis AG
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • PREVALENCE OF GENETIC DISORDERS (2012)
  • 8.2 GENETIC DISORDERS
  • Cytogenetic
  • Genetic Disorder
  • World
  • Market Size
  • Agilent Technologies, Inc.
  • PROPORTION OF DUCHENNE MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF DUCHENNE MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • Sarepta Therapeutics, Inc.
  • PROPORTION OF DOWN SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF DOWN SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • F. Hoffmann-La Roche Ltd.
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF FABRY DISEASE TO GENETIC DISORDERS CLINICAL TRIALS
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF FABRY DISEASE TO GENETIC DISORDERS CLINICAL TRIALS
  • Clinical Trial
  • Drug Discovery And Development
  • Genetic Disorder
  • World
  • Product Initiative
  • PROPORTION OF FRAGILE X SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF FRAGILE X SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS
  • Genetic Disorder
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF GAUCHER DISEASE TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF GAUCHER DISEASE TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Biopharmaceutical
  • Genetic Disorder
  • Pathology
  • World
  • Product Initiative
  • Clinical Trials by G7 Countries: Proportion of Becker Muscular Dystrophy to Genetic Disorders Clinical Trials
  • PROPORTION OF BECKER MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Genetic Disorder
  • Mental Health
  • Neurological Disorder
  • World
  • Product Initiative
  • PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Antiviral
  • Genetic Disorder
  • World
  • Product Initiative
  • Grifols, S.A.
  • Apr 18, 2016: Nivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President of Discovery

He has also served in several academic leadership positions, including director of the Center for Genetic Lung Disease at the University of Colorado School of Medicine, director of the Cystic Fibrosis Center at National Jewish Medical and Research Center and director of the Adult C

  • Genetic Disorder
  • Pharmaceutical
  • United States
  • Company
  • Nivalis Therapeutics, Inc.
  • Cystic Fibrosis Foundation Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017
  • CYSTIC FIBROSIS FOUNDATION THERAPEUTICS ENTERS INTO RESEARCH AGREEMENT WITH SHIRE
  • Cystic Fibrosis
  • Genetic Disorder
  • United States
  • Company
  • Cystic Fibrosis Foundation Therapeutics, Inc.
  • DEAL IN BRIEF
  • MAY 18, 2016: PROQR ANNOUNCES RESULTS FOR THE FIRST QUARTER OF 2016

We believe RNA therapeutics offers a powerful therapeutic approach to severe genetic disease.

  • Genetic Disorder
  • Genomics
  • United States
  • Company
  • ProQR Therapeutics N.V.
  • Clinical Trials by G7 Countries: Proportion of Polycystic Kidney Disease to Genetic Disorders Clinical Trials
  • Clinical Trials by E7 Countries: Proportion of Polycystic Kidney Disease to Genetic Disorders Clinical Trials
  • Genetic Disorder
  • Pharmaceutical
  • World
  • Product Initiative
  • Otsuka Pharmaceutical Co., Ltd.
  • PROPORTION OF ALPHA-MANNOSIDOSIS TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • PROPORTION OF ALPHA-MANNOSIDOSIS TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • Genetic Disorder
  • Neurological Disorder
  • Therapy
  • World
  • Product Initiative
  • Clinical Trials by G7 Countries: Proportion of Tay-Sachs Disease to Genetic Disorders Clinical Trials
  • Proportion of Tay-Sachs Disease to Genetic Disorders Clinical Trials, G7 Countries (%), 2016*
  • Genetic Disorder
  • Mental Health
  • Neurological Disorder
  • World
  • Product Initiative
  • Proportion of Becker Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2016*
  • Clinical Trials by E7 Countries: Proportion of Becker Muscular Dystrophy to Genetic Disorders Clinical Trials
  • Genetic Disorder
  • Neurological Disorder
  • World
  • Product Initiative
  • PTC Therapeutics, Inc.
  • Proportion of Von Hippel-Lindau Syndrome to Genetic Disorders Clinical Trials, G7 Countries (%), 2016*
  • Clinical Trials by G7 Countries: Proportion of Von Hippel-Lindau Syndrome to Genetic Disorders Clinical Trials
  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • Novartis AG
  • Clinical Trials by E7 Countries: Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials
  • Proportion of Alpha- Antitrypsin Deficiency to Genetic Disorders Clinical Trials, E7 Countries (%), 2016*
  • Genetic Disorder
  • Hepatitis Treatment
  • World
  • Product Initiative
  • Grifols, S.A.